Loading
A phase 2 trial of Adaptive radiotherapy in Head and neck squamous cell carcinoma, run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, now recruiting.
Response Adaptive Radiotherapy Following Immunotherapy-based Induction for Non-HPV Related HNSCC is a phase 2 interventional study registered as NCT06345287 by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, with 133 participants planned, started 2024-01-01 and due to reach its primary completion in 2025-12-31. Interventions recorded: radical radiotherapy (60Gy), radical radiotherapy (66Gy), radical radiotherapy (70Gy), anti-PD-1 or PD-L1 antibody. Conditions recorded: Head and Neck Cancer.
Linked to the technology Adaptive radiotherapy because the registry's title names it ("adaptive radiotherapy") and Head and neck squamous cell carcinoma among its conditions. Registry record only: no result has been read by an editor.
Shares HPV-positive oropharyngeal cancer, Head and neck squamous cell carcinoma and the tag pipeline.
Shares HPV-positive oropharyngeal cancer, Head and neck squamous cell carcinoma and the tag pipeline.
Shares Adaptive radiotherapy (online replanning) and the tag pipeline.
Shares Adaptive radiotherapy (online replanning) and the tag pipeline.
Shares HPV-positive oropharyngeal cancer, Head and neck squamous cell carcinoma and the tag pipeline.
Shares HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer), Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.